Psoriatic Arthritis Market, by Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Biologics, and Others), by Product Type (Prescription and Over The Counter), by Route of Administration (Topical, Or

Psoriatic Arthritis Market, by Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), Biologics, and Others), by Product Type (Prescription and Over The Counter), by Route of Administration (Topical, Oral, and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis — a condition that features red patches of skin topped with silvery scales. Most people develop psoriasis first and are later diagnosed with psoriatic arthritis, but the joint problems can sometimes begin before skin patches appear. Joint pain, stiffness, and swelling are the main signs and symptoms of psoriatic arthritis. Psoriatic arthritis can affect any part of your body, including your fingertips and spine, and can range from relatively mild to severe. Psoriatic arthritis can affect joints on just one side or on both sides of the body. The signs and symptoms of psoriatic arthritis often resemble those of rheumatoid arthritis. Psoriatic arthritis causes:
Swollen fingers and toes
Foot pain
Lower back pain

Market Dynamics

Key players are focused on gaining approvals from regulatory bodies in order to expand their product portfolio. This is expected to propel the growth of the global psoriatic arthritis market during the forecast period. For instance, in July 2013, Janssen-Cilag International NV (Janssen) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of STELARA (ustekinumab), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

Increasing number of drugs approvals from regulatory bodies is the major factor driving the market growth over the forecast period. For instance, in January 2019, Sandoz Canada Inc., a division of Novartis AG, announced that Health Canada has approved Erelzi (etanercept), a biosimilar of Enbrel (etanercept), for the treatment of psoriatic arthritis (PsA) in adult patients, making Erelzi the only etanercept biosimilar to have obtained approval for this indication in Canada.

Key features of the study:
This report provides an in-depth analysis of global psoriatic arthritis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global psoriatic arthritis market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include AbbVie, Inc., Amgen, Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer, Inc., UCB S.A., and AstraZeneca plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global psoriatic arthritis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the psoriatic arthritis market.
Detailed Segmentation:
Global Psoriatic Arthritis Market, By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDs)
Biologics
Others
Global Psoriatic Arthritis Market, By Product Type:
Prescription
Over The Counter
Global Psoriatic Arthritis Market, By Route of Administration:
Topical
Oral
Injectable
Global Psoriatic Arthritis Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Psoriatic Arthritis Market, By Region:
North America
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class:
Non-steroidal Anti-inflammatory Drugs (NSAIDS)
Disease-modifying Antirheumatic Drugs (DMARDS)
Biologics
Others
By Product Type:
Prescription
Over The Counter
By Route of Administration:
Topical
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
AbbVie, Inc. *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Amgen, Inc..
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Novartis International AG
Eli Lilly and Company
Pfizer, Inc.
UCB S.A.
AstraZeneca plc.
“*” marked represents similar segmentation in other categories in the respective section.